Lakefront Biotherapeutics NV (LKFT) stock
LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$34.39−0.40 (-1.15%)
Close on Nov 17, 2026Market cap $2.27BP/E 6.4Yield –
Lakefront Biotherapeutics r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was €459.42M, up 37.0% from the year before. Over ten years it grew 13.5% a year on average. The highest annual figure on record is €523.67M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | €459.42M | +37.0% |
| FY2024 | Dec 31, 2024 | €335.46M | +39.0% |
| FY2023 | Dec 31, 2023 | €241.29M | -10.6% |
| FY2022 | Dec 31, 2022 | €269.80M | -15.8% |
| FY2021 | Dec 31, 2021 | €320.50M | -38.8% |
| FY2020 | Dec 31, 2020 | €523.67M | +24.7% |
| FY2019 | Dec 31, 2019 | €420.09M | +32.8% |
| FY2018 | Dec 31, 2018 | €316.22M | +44.7% |
| FY2017 | Dec 31, 2017 | €218.50M | +56.6% |
| FY2016 | Dec 31, 2016 | €139.57M | +7.6% |
| FY2015 | Dec 31, 2015 | €129.71M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2021 | Jun 30, 2021 | €138.87M | +189.4% |
| Q2 FY2020 | Jun 30, 2020 | €147.45M | – |
| Q2 FY2019 | Jun 30, 2019 | €94.37M | – |
| Q2 FY2018 | Jun 30, 2018 | €81.68M | – |
| Q2 FY2017 | Jun 30, 2017 | €47.98M | – |
See a number that looks wrong?